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mortality risk and end-stage renal disease (ESRD) have 
been studied in a meta-analysis  [2] .
 Our objective was to compare relative risks and abso-
lute risks for all-cause mortality among adults stratified 
by eGFR, ACR, and demographic categories. Previous 
publications have emphasized an attenuation of relative 
risk for all-cause mortality for older individuals com-
pared to younger individuals  [3–5] , and have suggested 
adoption of an age-calibrated definition of CKD. We now 
report similar apparent attenuation of relative risk for all-
cause mortality for female gender and black subjects in 
the study cohort. Rather than adopting strata-specific 
definitions of CKD, we believe the same ultimate goal can 
be achieved by adopting strata-specific risk summaries 
(“heat maps”) to describe the risk for all-cause mortality.
 Materials and Methods 
 The Reasons for Geographic and Racial Differences in Stroke 
(REGARDS) study cohort included 30,239 black and white indi-
viduals who were  ≥ 45 years, between January 2003 and October 
2007  [6, 7] . Additional methodological details and description of the 
cohort are provided elsewhere  [6–8] . The present analysis excluded 
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 Abstract 
 The relative reduction of risk for all-cause mortality among 
the elderly has been described as attenuated compared to 
younger subjects, but the risk for all-cause mortality increas-
es with age when absolute risk is considered. The objectives 
of the present inquiry were to calculate the relative and ab-
solute risks of all-cause mortality based on incidence rate ra-
tios, and summarize these risks for age, gender, and race stra-
ta. We conclude that strata-specific risk summaries are more 
informative than a single all-encompassing risk summary, 
and that gender- and race-specific strata need to be consid-
ered as well as age-specific strata.   © 2017 S. Karger AG, Basel 
 Introduction 
 Chronic kidney disease (CKD) staging, based on esti-
mated glomerular filtration rate (eGFR) categories, was 
recently revised to include risk strata for urinary 
 albumin-to-creatinine ratio (ACR)  [1] . The associations 
between eGFR and ACR categories by age for all-cause 
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participants with missing values for covariates. The effect variable 
was the standardized creatinine-based CKD-Epidemiology Collab-
oration eGFR  [9] . All-cause mortality was ascertained as previously 
described  [6–8] . The UAB Institutional Review Board approved the 
protocol and all participants gave written informed consent.
 Mortality Rates, Incidence Rates and Absolute Rates for 
All-Cause Mortality 
 Mortality rates (percentage), incidence rates (per 1,000-person 
years; Stata command stptime), and incidence rate ratios with ±95% 
CIs were calculated with multi-variable adjusted Poisson regres-
sion models for eGFR strata (>100, 80–100, 60–80, 45–60, and <45 
mL/min/1.73 m 2 ), ACR strata (<30 and  ≥ 30 mg/g), and age strata 
(<60, 60–70, and >70 years). Absolute incidence rates were ob-
tained from the incidence rate ratios by multiplying each by the 
rate for eGFR for 80–100 mL/min/1.73 m 2 , ACR <30 mg/g, and age 
<60 years  [10] .
 Dunnett method was used for making comparisons with a refer-
ence category for pairwise comparisons of means. Incidence rate 
ratios were calculated with Poisson regression for eGFR deciles be-
tween 25 and 125 mL/min/1.73 m 2 . Mean values (±95% CI) are used 
as the relative risk for each interval with covariates fixed at their 
mean values (Stata command margins, atmeans). Stata (version 
14.1, College Park Station, TX, USA) was used for statistical analysis.
 Results 
 Baseline Characteristics 
 Baseline characteristics and deaths are shown for 
the age strata in  Table 1 for 26,887 with 3,989 deaths 
(15%). Of the entire cohort, 40% were African– 
American and 25% were <58 years of age at enrollment. 
Male preponderance, systolic blood pressure, prevalent 
cardiovascular disease, albuminuria >30 mg/dL, and 
eGFR <60 mL/min/1.73 m 2 increased across the age 
strata. The number of blacks, total cholesterol, and cur-
rent smoking status decreased across the age strata. 
As  expected, all-cause mortality rates increased with 
age.
 Risk Summaries for All-Cause Mortality: “Heat Maps” 
 Table 2 a shows all-cause mortality across age, eGFR, 
and ACR strata, with the number of deaths expressed as 
a percentage. Higher mortality rates were associated with 
lower eGFR categories, and especially for subjects with 
Table 1.  Baseline characteristics and outcomes for age-strata: 26,887 participants with 3,980 deaths (15%), excluding participants with 
missing values
Characteristics Totala Age: ≤60a Age: 60–70a Age: ≥70a
Patients, n (%) 26,887 (100) 9,384 (35) 9,215 (34) 8,288 (31)
Age, years, median (IQR) 64 (58–71) 56 (52–58) 65 (63–67) 75 (72–79)b
Males, % 12,251 (46) 3,836 (41) 4,322 (47) 4,093 (49)b
Blacks, %c 10,670 (40) 4,084 (44) 3,689 (40) 2,897 (35)b
eGFR_creat, mL/min/1.73 m2, mean (SD) 86 (19) 96 (17) 86 (17) 74 (18)b
eGFR_creat <60 mL/min/1.73 m2, % 2,760 (10.3) 260 (2.8) 726 (7.9) 1,774 (21)b
ACR >30 mg/g, % 3,796 (14) 986 (11) 1,207 (13) 1,603 (19)b
SBP, mm Hg, mean (SD) 127 (17) 124 (16) 128 (16) 131 (17)b
Total cholesterol, mean (SD) 192 (40) 197 (40) 193 (40) 187 (40)b
BMI, kg/m2, median (IQR) 28 (25–32) 29 (25–34) 29 (25–33) 27 (24–31)b
CVD, % 5,692 (21) 1,192 (13) 1,944 (21) 2,556 (31)b
Diabetes, % 5,413 (20) 1,627 (17) 2,026 (22) 1,760 (21)
Current smoking, % 3,820 (14) 1,860 (20) 1,315 (14) 645 (7.8)b
Outcomes, %
Deaths, % 3,980 (15) 505 (5.4) 1,032 (11) 2,443 (30)b
Incidence rate, per 1,000-person years 21.3 (20.7–22.0) 7.7 (7.1–8.5) 15.5 (14.6–16.5) 45 (43–46)b
Incidence rate ratio 1.00 (reference) 2.00 (1.80–2.22) 5.74 (5.22–6.32)b
 Values are given as number (percentage), means (SD); medians (IQR); incidence rates and incidence rate ratios (95% CI).
ACR, urinary albumin-to-creatinine ratio; BMI, body mass index; CVD, prevalent cardiovascular disease; eGFR_creat, creatinine-
based estimated glomerular filtration rate, CKD Epidemiology Collaboration; IQR, interquartile range, 25th–75th quartile; SBP, systolic 
blood pressure.
p < 0.001, bold text used to indicate significance for comparisons of characteristics to the reference group by ANOVA for means, 
signed rank test for medians, and chi-square test for proportions.
a Row percentages; all others are column percentages. 
b p < 0.05 for comparison between 3rd and 2nd categories (Dunnett test for multiple comparisons) or chi-square test or proportions.


























   
   
   
   
   
   
   























a.  Counts and all-cause mortality rates: age, eGFR, and ACR strataa
eGFR_creat, 
mL/min/1.73 m2
Age: <60 Age: 60–70 Age: >70
ACR <30 mg/g ACR ≥30 mg/g ACR <30 mg/g ACR ≥30 mg/g ACR <30 mg/g ACR ≥30 mg/g
>100 3,370 439 1,430 241 370 80
151 (4.5) 50 (11) 146 (10) 46 (19) 67 (18) 28 (35)
80–100 3,825 309 3,897 418 2,667 480
141 (3.7) 31 (10) 315 (8.1) 86 (21) 597 (22) 178 (37)
60–80 1,037 144 2,189 314 2,437 480
64 (6.2) 19 (13) 200 (9.1) 65 (21) 606 (25) 206 (43)
45–60 145 51 396 137 893 319
15 (10) 11 (22) 49 (12) 44 (32) 288 (32) 163 (51)
<45 21 43 96 97 318 244
3 (14) 20 (47) 20 (21) 61 (63) 139 (44) 171 (70)
 Values are n or n (%).
a The mortality rates were calculated as the percentage of deaths in each cell.
b. Relative risk (±95% CI) for all-cause mortality: age, eGFR, and ACR stratab
eGFR, 
mL/min/1.73 m2
Age: <60 Age: 60–70 Age: >70
ACR <30 mg/g ACR ≥30 mg/g ACR <30 mg/g ACR ≥30 mg/g ACR <30 mg/g ACR ≥30 mg/g
>100 1.20 (0.95–1.52) 2.49 (1.77–3.49) 1.12 (0.97–1.38) 1.78 (1.29–2.45) 0.87 (0.67–1.12) 1.57 (1.07–2.31)
80–100 1.00 (reference)a 2.02 (1.36–3.01) 1.00 (reference)a 2.28 (1.79–2.91) 1.00 (reference)a 1.69 (1.42–2.00)
60–80 1.58 (1.17–2.12) 2.28 (1.40–3.73) 1.12 (0.94–1.34) 1.92 (1.46–2.53) 1.13 (1.01–1.26) 1.88 (1.60–2.12)
45–60 2.11 (1.23–3.61) 4.00 (2.13–7.51) 1.47 (1.08–1.99) 3.21 (2.32–4.43) 1.48 (1.28–1.70) 2.38 (2.00–2.84)
<45 2.96 (0.94–9.30) 6.80 (4.08–11.3) 2.59 (1.64–4.08) 7.13 (5.36–9.50) 2.22 (1.84–2.67) 3.71 (3.12–4.42)
a Incidence rate ratio; relative to reference group for each age strata.
Color coding for relative risk of all-cause mortality: green, <1.5; yellow, >1.5 and <2.5; orange, >2.5 and <4.0; red, >4.0. Color 
version available online.
c. Absolute incidence rate (±95% CI) for all-cause mortality: age, eGFR, and ACR stratab
eGFR, 
mL/min/1.73 m2
Age: <60 Age: 60–70  Age: >70
ACR <30 mg/g ACR ≥30 mg/g ACR <30 mg/g ACR ≥30 mg/g ACR <30 mg/g ACR ≥30 mg/g
>100 1.23 (0.05–2.42) 5.37 (3.71–7.04) 4.25 (3.05–5.45) 6.99 (5.27–8.71) 7.29 (5.78–8.80) 10.1 (8.02–12.2)
80–100 5.13 (4.35–6.05)* 4.25 (2.26–6.26) 3.32 (2.30–4.34) 7.95 (6.57–934) 8.40 (7.45–9.35) 10.9 (9.71–12.0)
60–80 2.53 (1.02–4.05) 5.30 (2.82–7.77) 3.94 (2.83–5.05) 7.32 (5.80–8.84) 8.99 (8.04–9.94) 11.3 (10.2–12.4)
45–60 4.89 (2.15–7.62) 8.21 (5.05–11.4) 5.46 (3.79–7.13) 9.93 (8.14–11.7) 10.3 (9.34–11.3) 12.5 (11.3–13.7)
<45 6.32 (0.46–12.2) 11.5 (8.96–14.0) 8.47 (6.06–10.9) 14.1 (12.6–15.7) 12.4 (11.1–13.6) 14.8 (13.6-16.0)
a Incidence rate; deaths per 1,000 patient year.
The incidence rate ratios in Table 2c were calculated for each gender and age >70 years; the reference group had eGFR >80 and 
<100 mL/min/1.73 m2 and ACR <30 mg/g creatinine. 
Color coding for absolute risk of all-cause mortality: green, <6.0; yellow, >6.0 and <8.0; orange, >8.0 and <12.0; red, >12.0. Color 
version available online.
The absolute mortality rates (Table 3b) for each cell were obtained by multiply the incidence rate ratios by the mortality rate for 
the eGFR 80–100, ACR <30 mg/g group in column 1 (indicated by*).
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ACR >30 mg/g. As expected, higher mortality rates were 
observed with increasing age categories for all strata.
 Relative risks for mortality across the age strata, rela-
tive to a common reference at eGFR between 80 and 100 
mL/min/1.73 m 2 and ACR <30 mg/g are shown in 
 Table 2 b. Arbitrary color coding corresponds to increas-
ing relative risk (see legend). The relative risk for all-cause 
mortality was attenuated for older subjects, and the rela-
tive risk is similar for eGFR strata >45 mL/min/1.73 m 2 
and ACR <30 mg/g.
 Table 2 c shows the absolute risk for mortality across 
the age strata. Incidence rate ratios were calculated rel-
ative to a common reference at eGFR between 80 and 
100 mL/min/1.73 m 2 , ACR <30 mg/g, and age <60 
years. Arbitrary color coding corresponds to increasing 
absolute risk (see legend). The absolute risk for all-
cause mortality was increased for older REGARDS 
 participants (age >70 years), and the absolute risk was 
similar for eGFR strata >45 mL/min/1.73 m 2 , and ACR 
<30 mg/g was similar for subjects <70 years. The 
 absolute risk for mortality increased with age and ACR 
>30 mg/g.
 Table 3 shows the relative risk for mortality for race 
and gender strata, among subjects >70 years of age. 
 Arbitrary color coding corresponds to increasing abso-
lute risk (see legend). The relative risk for all-cause mor-
tality was attenuated for black subjects compared to white 
subjects >70 years of age ( Table 3 a), and for female sub-
jects compared to male subjects >70 years of age and ACR 
<30 mg/g ( Table 3 b).
 Discussion 
 We describe mortality risk for REGARDS participants 
based on demographic strata, eGFR, and ACR categories 
using incidence rates and incidence rate ratios for all-
cause mortality. Risk summaries (“heat maps”) show no-
table differences across demographic strata.
 The relative risks for all-cause mortality were attenu-
ated for the older age strata ( Table 2 b), while the abso-
lute risk for mortality increased with age ( Table 2 c). For 
example, the relative risks for mortality among partici-
pants with eGFR >60 and <80 mL/min/1.73 m 2 , and 
Table 3
a.  Relative risk (±95% CI) for all-cause mortality: race, age >70, eGFR, and ACR strataa
eGFR, 
mL/min/1.73 m2
Age: >70 Age: >70; white  Age: >70; black
ACR <30 mg/g ACR ≥30 mg/g ACR <30 mg/g ACR ≥30 mg/g ACR <30 mg/g ACR ≥30 mg/g
>100 0.87 (0.67–1.12) 1.57 (1.07–2.31) 1.67 (0.86–3.24) 9.09 (2.91–28.4) 0.80 (0.60–1.08) 1.44 (0.94–2.19)
80–100 1.00 (reference)a 1.69 (1.42–2.00) 1.00 (reference)a 1.83 (1.49–2.24) 1.00 (reference)a 1.45 (1.08–1.96)
60–80 1.13 (1.01–1.26) 1.88 (1.60–2.12) 1.10 (0.96–1.26) 1.87 (1.53–2.28) 1.17 (0.95–1.44) 1.90 (1.44–2.50)
45–60 1.48 (1.28–1.70) 2.38 (2.00–2.84) 1.54 (1.30–1.81) 2.34 (1.88–2.82) 1.34 (1.03–1.75) 2.42 (1.80–3.26)
<45 2.22 (1.84–2.67) 3.71 (3.12–4.42) 2.14 (1.71–2.69) 3.21 (2.54–4.06) 2.30 (1.65–3.21) 4.58 (3.50–6.00)
b. Relative risk for all-cause mortality: gender, age >70, eGFR, and ACR strataa
eGFR, 
mL/min/1.73 m2
Age: >70 Age: >70; males Age: >70; females
ACR <30 mg/g ACR ≥30 mg/g ACR <30 mg/g ACR ≥30 mg/g ACR <30 mg/g ACR ≥30 mg/g
>100 0.87 (0.67–1.12) 1.57 (1.07–2.31) 1.27 (0.91–1.77) 1.25 (0.70–2.25) 0.57 (0.38–0.87) 1.95 (1.17–3.27)
80–100 1.00 (reference)a 1.69 (1.42–2.00) 1.00 (reference)a 1.72 (1.38–2.14) 1.00 (reference)a 1.68 (1.29–2.20)
60–80 1.13 (1.01–1.26) 1.88 (1.60–2.12) 1.21 (1.05–1.40) 1.91 (1.55–2.34) 1.00 (0.83–1.20) 1.90 (1.46–2.46)
45–60 1.48 (1.28–1.70) 2.38 (2.00–2.84) 1.62 (1.34–1.95) 2.54 (2.04–3.17) 1.30 (1.05–1.62) 2.15 (1.61–2.88)
<45 2.22 (1.84–2.67) 3.71 (3.12–4.42) 2.57 (1.98–3.35) 3.47 (2.75–4.38) 1.87 (1.43–2.43) 4.12 (3.18–5.35)
 a Incidence rate ratio; relative to the reference group for each age strata.
Color coding for absolute risk of all-cause mortality: light green, <1.0; green, >1 and <1.5; yellow, >1.5 and <2.5; orange, >2.5 and 
<4.0; red, >4.0. Color version available online.
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ACR <30 mg/g was 1.58 (95% CI 1.17–2.12) for age <60 
years; 1.12 (95% CI 0.94–1.34) for age >60 and <70 
years; and 1.13 (95% CI 1.01–1.26) for age >70 years 
( Table 2 b). In contrast, the absolute risk for mortality 
among the same participants was increased across the 
age strata: 2.53 (95% CI 1.02–4.05) for age <60 years; 
3.94 (95% CI 2.83–5.05) for age >60 and <70 years; and 
8.99 (95% CI 8.04–9.94) for age >70 years ( Table 2 c). 
Similar patterns were seen across the same eGFR and 
age strata for ACR >30 mg/g.
 Previous commentaries have emphasized the attenua-
tion of the relative risk for all-cause mortality among old-
er subjects  [4] . The present analysis confirms this finding, 
but also extends the analysis to show the expected in-
crease in absolute risk for all-cause mortality with in-
creasing age. Similar observations about the increase in 
mortality rates with age and ACR levels are described by 
Hallan et al.  [2] .
 Furthermore, the gender and race differences in rela-
tive risk for all-cause mortality shown in  Table 3 a and b 
suggest that these strata as well as age should also be con-
sidered when assessing the relative risk for all-cause mor-
tality among a specified cohort of patients. This conclu-
sion is consistent with longitudinal descriptions of the 
risk for all-cause mortality described for elderly Swedish 
women  [11] .
 The KDIGO Controversies Conference Report  [10] 
included “heat maps” for separate outcome events, in-
cluding all-cause mortality, cardiovascular mortality, 
ESRD, acute kidney injury, and progressive CKD. The 
relative risk summary table for all-cause mortality  [10] is 
similar to the absolute risk summary. It used similar ref-
erence groups (ACR <10 and <30 mg/g, eGFR 90–105 
and 80–100 mL/min/1.73 m 2 ), with mortality incidence 
rates of 7.0 and 5.13 deaths per 1,000-person years, re-
spectively. Absolute risk in  Table  2 c was generated by 
multiplying incidence rate ratios by the absolute risk for 
the reference group, as previously described  [10] . As ex-
pected, the risk for all-cause mortality increased with 
 aging.
 With the goal of confirming a single all-encompassing 
risk summary scheme  [1] , Hallan et al. [2] examined risk 
summaries for age strata, eGFR, and ACR categories with 
a meta-analysis of 33 general population cohorts, includ-
ing over 2 million participants with 112,325 deaths, in-
cluding 27,306 REGARDS participants. Risk for all-cause 
mortality differ across age strata, both for relative risk and 
absolute risk  [2] , supporting the use of different risk sum-
maries for different outcome events, demographic strata, 
and eGFR and ACR strata.
 We conclude that the differences between relative and 
absolute risks for all-cause mortality have not received 
sufficient emphasis. Furthermore, there may be differ-
ences in the absolute and relative risks across age-strata 
that require further analyses for gender and race strata. 
The REGARDS cohort is not large enough to fully define 
these strata, and was recruited with the goal of including 
subjects >45 years of age, and an equal number of men, 
women, and white and black participants. Additional me-
ta-analysis of combined general population cohorts 
seems worthwhile.
 It has been proposed that the cutpoints for CKD stag-
es be adjusted for age strata, described as an age-calibrat-
ed definition of CKD  [3–5] , to account for the attenuation 
of relative risk for all-cause mortality observed with older 
subjects. This approach has not been widely accepted 
 [12] , and represents a post-hoc modification of risk as-
sessment that does not address the underlying weakness-
es inherent when such analyses include eGFR as an effect 
variable  [8] . The current proposal to use separate heat 
maps for age, race, and gender strata rather than a single 
all-encompassing risk summary may accomplish the ba-
sic goal of providing risk assessments in CKD that reflect 
the demographic and kidney-specific factors for an indi-
vidual patient.
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